This study is a Phase II, randomized, quadruple-blinded, placebo-controlled clinical trial designed to test whether vitamin D₃ supplementation can improve recovery after mild-to-moderate traumatic brain injury (TBI) in adults.
Traumatic brain injury often leads to inflammation and poor neurological outcomes, and many patients are vitamin D-deficient. Vitamin D₃ is a safe, widely available supplement that may reduce inflammation and support brain recovery.
A total of 240 adults (18-65 years) with mild-to-moderate TBI will be enrolled at Lagos State University Teaching Hospital, Nigeria. Participants will be assigned to one of four groups:
Group A (Deficient + High-Dose D₃): 40,000 IU loading dose, then 4,000 IU daily for 3 weeks Group B (Deficient + Standard-Dose D₃): 2,000 IU daily for 3 weeks Group C (Sufficient + Standard-Dose D₃): 2,000 IU daily for 3 weeks Group D (Sufficient + Placebo): placebo daily for 3 weeks All groups will be followed for 24 weeks. Blood tests at baseline, week 1, week 2, and week 4 will measure inflammation. Neurological recovery will be assessed at weeks 4, 12, and 24 using the Glasgow Outcome Scale-Extended (GOS-E) and Modified Rankin Scale (mRS).
The main outcomes are changes in inflammatory markers. Secondary outcomes include mortality, functional recovery, hospital stay, safety, and cost-effectiveness.
The results may identify a low-cost, scalable treatment to improve outcomes after TBI, especially in low-resource settings.

Start Date02 Jan 2026

Sponsor / Collaborator

Lagos State University

CTRI/2025/11/097258

/ Not yet recruitingPhase 3

Comparative evaluation of efficacy of DFDBA and DFDBA enriched with Vitamin D3 in alveolar socket preservation A Clinical Radiographic and Histologic study - NIL

Start Date02 Jan 2026

Sponsor / Collaborator-

CTRI/2025/11/096747

/ Not yet recruitingPhase 4IIT

Role of intralesional Vitamin D3 in the treatment of cutaneous warts– At aTertiary Care Center in Central Karnataka - Nil

Start Date01 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

23,678

Literatures (Medical) associated with Colecalciferol

01 Feb 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Highly sensitive and selective fluorescent detection of vitamin D3 in human serum using carbon quantum dots/nano-graphite hybrid sensor

Article

Author: Wei, Yin ; Zhang, Junbo ; Wang, Yujia ; Li, Zhi ; Xu, Xinqiu ; Wang, Qihui ; Yan, Yehao ; Wang, Ziheng

This study explores the use of carbon quantum dots (CQDs), aptamers (Apt), and nanographite (NG) for fluorescent sensing of vitamin D. CQDs-Apt conjugates adsorb onto the surface of NG via π-π stacking interactions, inducing an internal filter effect (IFE) that quenches the intrinsic fluorescence of the CQDs-Apt complex. In the presence of vitamin D, this internal filter effect is disrupted, resulting in the recovery of fluorescence from the CQDs-Apt conjugates. The sensor exhibits a linear response range from 0 to 900 nM with a detection limit of 20.87 nM (calculated using the 3σ method). Importantly, this sensor has been successfully applied to detect vitamin D in blood samples. Furthermore, the aptamer sensors based on carbon quantum dots can effectively distinguish the interfering substances in serum. This technology offers advantages such as high sensitivity, selectivity, simplicity of operation, thus opening new avenues for the development of vitamin sensing platforms.

01 Feb 2026·Archivos Argentinos de Pediatria

Experience with denosumab in the treatment of bone diseases in pediatrics at a tertiary care hospital

Author: Ciaccio, Marta ; Feller, Ana ; Rosé, Adriana ; Insúa Beverina, María de Los Ángeles ; Bermejo, Natalia ; Fortunati, Daniela ; Aziz, Mariana ; Viso, Marianela ; Soria, Ianina ; Viterbo, Gisela ; Gil, Silvia

Denosumab has been shown to improve post-surgical morbidity in resectable lytic bone neoplasms with high RANK-L expression and to halt disease progression in unresectable cases. Intra- and post-treatment adverse effects have been reported. We conducted a prospective, descriptive study including six patients with lytic bone neoplasms treated with denosumab. The median age at onset treatment was 7.4 years, and the male-to-female ratio was 5:1. Five patients showed a favorable response. All patients developed hypocalcemia and hypophosphatemia during treatment, requiring adjustments in calcium and ergocalciferol/cholecalciferol supplementation (6/6), the addition of calcitriol (5/6), and phosphate salts (3/6). Metaphyseal bands were observed in 4 out of 6 patients. No fractures were reported, and most patients did not show evidence of impaired growth. Four patients experienced post-treatment hypercalcemia. Risk factors included younger age, a higher number of doses, and the presence of metaphyseal bands.

01 Feb 2026·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Vitamin D3 and vitamin A synergistically prevent visuospatial memory impairment in mice model of the dopaminergic system disorder

Article

Author: Oyem, John C ; Usman, Yusuf ; Atuadu, Vivian ; Badamasi, Ibrahim M ; Shehu, Kabir ; Umar, Sirajo M

Motor, visual, and cognitive decline are early signs of dopaminergic system dysfunction (DSD), yet the mechanisms underlying associated visuospatial memory impairment are poorly understood. This study evaluated visuospatial memory in DSD and the neuroprotective effects of vitamins D3 and A. Animals were grouped as NS (control), -D2 (15 mg/kg Haloperidol), -D2+VD (Haloperidol + 800 IU vitamin D3), -D2+VA (Haloperidol + 1000 IU vitamin A), -D2+(VD+VA) (Haloperidol + vitamins D3 and A), and -D2+D2 (Haloperidol + 10 mg/kg Bromocriptine). Visuospatial memory was assessed using the visual water box and Y-maze tests. Brain regions and retina were analyzed for histology, immunohistochemistry, oxidative stress, and ELISA for TNF-α, IL-6, IL-4, IL-13, and dopamine. DSD induced significant visuospatial memory deficits, decreased SOD, IL-4, and IL-13, and increased TNF-α, IL-6, LDH, MDA, reactive astrocytes, degenerating neurons, and extracellular fibrils. Vitamin D alone was moderately effective, while combined vitamin D and A treatment more effectively regulated IL-6, IL-13, MDA, and reactive astrocytes in the prefrontal cortex and hippocampus. Other parameters were similarly improved by single or combined treatment. Dopaminergic system dysfunctions are linked to visuospatial memory impairment due to increased cytotoxicity, pro-inflammatory cytokines, oxidative stress, neural alterations, and reactive astrocyte expression, leading to reduced dopamine concentration in the PFC, HPC, visual cortex, and retina. Administration of vitamin A and D is more potent in providing a defensive mechanism by downregulating oxidative stress, reactive astrocytes, and their associated proinflammatory cytokines. All of which contribute to the regulation of dopamine levels.

160

News (Medical) associated with Colecalciferol

10 Nov 2025

·www.sciencedaily.com

Vitamin D3 breakthrough halves risk of second heart attack

Intermountain Health researchers discovered that customizing vitamin D3 doses for heart attack survivors slashed their risk of another heart attack by 50%. The strategy involved frequent monitoring and dose adjustments to reach ideal vitamin D levels. Traditional studies didn’t track blood levels, missing this critical link. A new study from Intermountain Health in Salt Lake City reports that a personalized vitamin D3 treatment plan for patients who have suffered a heart attack can greatly reduce their chances of another one. In a large randomized clinical trial, researchers found that managing patients' vitamin D levels through a "target-to-treat" approach -- where blood levels were monitored and dosages were adjusted to reach an optimal range -- cut the likelihood of a second heart attack by 50%. The findings were presented on Nov. 9 at the 2025 American Heart Association Scientific Sessions in New Orleans. Encouraging Early Results from Intermountain Researchers These results are very encouraging, said Heidi May, PhD, cardiovascular epidemiologist at Intermountain Health and the study's principal investigator. "We observed no adverse outcomes when giving patients higher doses of vitamin D3 supplementation, and to significantly reduce the risk of another heart attack, which are exciting results," said Dr. May. "We're excited with these results but know we have further work to do to validate these findings." According to researchers, the results carry global importance, as between one-half and two-thirds of people worldwide have low levels of vitamin D. In the past, most individuals received sufficient vitamin D through sunlight exposure. Today, with lifestyle changes and medical advice aimed at reducing skin cancer risk, people spend less time in the sun and must rely more on dietary supplements such as vitamin D3 to maintain healthy levels. From Observation to Precision Treatment Low vitamin D levels have long been linked to poor cardiovascular outcomes in observational studies. However, earlier clinical trials that provided standard supplementation doses failed to show measurable reductions in heart disease risk. Intermountain scientists wanted to test a different idea: rather than giving everyone the same dose, what if supplementation was adjusted to reach a specific, healthy vitamin D level? "Previous studies just gave patients supplementation without regularly checking blood levels of vitamin D to determine what supplementation achieved," said Dr. May. "With more targeted treatment, when we checked exactly how supplementation was working and made adjustments, we found that patients had their risk of another heart attack cut in half." Inside the TARGET-D Clinical Trial The Intermountain study, called the TARGET-D trial, ran from April 2017 to May 2023 and included 630 patients who had suffered a heart attack within a month of enrolling. Participants were followed until March 2025 to monitor cardiovascular outcomes. Patients were randomly assigned to one of two groups: one received no vitamin D management, and the other underwent active, targeted vitamin D3 treatment. The goal for the treatment group was to raise blood vitamin D levels to above 40 nanograms per milliliter (ng/mL). At the start, 85% of participants had vitamin D3 levels below that threshold (<40 ng/mL). Dosing, Monitoring, and Results More than half of the patients receiving targeted therapy required an initial dose of 5,000 international units (IU) of vitamin D3, compared to typical supplement recommendations of 600-800 IU. Vitamin D blood levels were checked annually for those maintaining healthy levels. Patients with lower levels were tested every three months and had their dosage adjusted until reaching the 40 ng/mL target. Afterward, their levels were monitored once a year. Researchers tracked major cardiac events (MACE), including heart attacks, strokes, heart failure hospitalizations, or deaths. Out of 630 participants, 107 experienced such events. While there was no significant difference in the overall risk of MACE between the two groups, the chance of having a second heart attack was cut in half among those receiving targeted vitamin D treatment. Next Steps for Heart and Vitamin D Research Researchers plan to expand their work with a larger clinical trial to confirm and build upon these findings. A larger study group will allow us to more fully evaluate whether targeted vitamin D management can reduce not only repeat heart attacks but also other forms of cardiovascular disease, said Dr. May.

AHAClinical Study

18 Aug 2025

·www.otsuka.co.jp

Research Findings on Skin Condition Fluctuations and Recommended Foods During the Menstrual Cycle

Otsuka Pharmaceutical Co., Ltd. (Otsuka) has women's health as one of its focus areas, including the unique challenges women face throughout different life stages. To support this, we are actively engaged in both research and awareness-raising initiatives. In a recent study published in the Journal of the Japan Society for Menopause and Women's Health, we examined skin changes associated with the menstrual cycle. Our findings categorized these changes by severity and suggested that a jelly drink containing equol, vitamin D, collagen, calcium, and magnesium (the "test food") may help improve skin condition following menstruation. ■ Our Findings Subjective skin evaluations showed that, without the test food, participants experienced improved overall skin conditions from Day 6 to Day 13 of the menstrual cycle. However, these improvements were reduced by the onset of the next cycle. In contrast, when the test food was consumed for six days following menstruation, the skin score from day 6 to day 13 showed a significant enhancement compared to the non-intake period. In addition, the consumption of the test food suppressed the deterioration of skin scores at the beginning of the next menstrual period (Figure 1). Objective assessments further supported this effect, with significant improvements observed in skin smoothness scores from Day 6 to Day 13 (Figure 2). These results indicate that the test food may contribute to better post-menstrual skin condition. Additionally, six days of test food consumption led to an increase in serum 25(OH)D₃, the storage form of vitamin D, which remained elevated for one week after discontinuation. This is the first study to evaluate the effects of a short-term (six-day) intervention using a low dose (20 µg) of vitamin D₃ in Japanese women. Subjective skin evaluations showed that, without the test food, participants experienced improved overall skin conditions from Day 6 to Day 13 of the menstrual cycle. However, these improvements were reduced by the onset of the next cycle. In contrast, when the test food was consumed for six days following menstruation, the skin score from day 6 to day 13 showed a significant enhancement compared to the non-intake period. In addition, the consumption of the test food suppressed the deterioration of skin scores at the beginning of the next menstrual period (Figure 1). Objective assessments further supported this effect, with significant improvements observed in skin smoothness scores from Day 6 to Day 13 (Figure 2). These results indicate that the test food may contribute to better post-menstrual skin condition. Additionally, six days of test food consumption led to an increase in serum 25(OH)D₃, the storage form of vitamin D, which remained elevated for one week after discontinuation. This is the first study to evaluate the effects of a short-term (six-day) intervention using a low dose (20 µg) of vitamin D₃ in Japanese women. ■ Summary: This study investigated the impact of menstrual cycle-related hormonal fluctuations on skin conditions and the potential benefits of foods containing equol, vitamin D, collagen, calcium, and magnesium. A non-blind crossover trial was conducted with 109 premenopausal women who reported experiencing changes in their skin conditions throughout their menstrual cycles. The first day of menstruation was considered Day 1, the participants consumed the test food for 6 consecutive days starting Day 7 during the test food intake period. The skin condition was evaluated subjectively with a self-administered questionnaire and objectively with a physiological assessment. The results demonstrated a significant improvement in the skin condition from Days 6 to 13 during the non-intake period. Conversely, significant deterioration was observed from Day 6 to the beginning of the next menstruation period. During the test food intake period, significant improvements were observed in several areas, including skin roughness. Moreover, these improvements were more pronounced in equol non-producers. This suggests that the consumption of the test food post-menstruation can potentially enhance the skin condition and suppress the deterioration typically experienced at the beginning of the next menstruation cycle. Menopause&Women's Health Jpn 32: 686-698, 2025 Reprint requests: Haruna Miyakawa, Nutraceuticals Research Institute, R&D Headquarters, Nutracenticals Division Otsuka Pharmaceutical Co., Ltd., Reprint requests: Haruna Miyakawa, Nutraceuticals Research Institute, R&D Headquarters, Nutracenticals Division Otsuka Pharmaceutical Co., Ltd., ■ About Equol Equol is a metabolite of soy isoflavone daidzen, which is produced through the action of intestinal bacteria. It is attracting attention for its potential to support women's health and beauty due to its ability to mimic the action of female hormones. However, not everyone can produce equol naturally; studies suggest that only around half of the Japanese population has the gut microbiota necessary to generate it.*1 ■ Otsuka's Initiatives to Promote Women's Health Otsuka has long been committed to addressing the physical and mental changes women experience across different life stages. Our research into menopausal symptoms and premenstrual syndrome (PMS) began in 1996. In 2002, we successfully isolated Lactococcus 20-92, a strain capable of producing equol. Since then, we have conducted extensive domestic and international research on the efficacy and safety of equol derived from fermented soybean sprouts using this strain. In addition to our research, we collaborate with medical professionals to offer seminars and online resources that provide women with accessible, reliable information. Through these efforts, we aim to support women in managing their health and enhancing their quality of life at every stage. Reference：Corporate Website: Women's Health https://www.otsuka.co.jp/en/nutraceutical/about/womens-health/ About Otsuka Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit. www.otsuka.co.jp/en/

Clinical Result

04 Aug 2025

·www.globenewswire.com

New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement That’s Gentle on the Stomach and Easy to Take

WATFORD, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A new generation of vitamin supplementation has arrived in the UK. IBSA, the Swiss-based pharmaceutical company, has launched a groundbreaking Iron Orodispersible Film (ODF), a thin, fast-dissolving supplement strip designed to deliver iron and folic acid without the need for water or swallowing tablets. At a time when up to a third of UK adults report difficulty swallowing pills¹, and many struggle with the gastrointestinal side effects of traditional iron supplements², IBSA Iron ODF offers a welcome solution. Using IBSA’s patented FilmTec® technology, this small, lemon-flavoured strip melts in the mouth quickly, delivering a precise dose of 30 mg iron (as ferric pyrophosphate) and 400 μg folic acid with minimal digestive discomfort.“I’ve been taking Iron supplements for over 10 years and tried so many types, tablets, liquids, you name it. They all made me feel sick with nausea and even vomiting. Since I started using the ODF Iron, I haven’t had any of those side effects, and I still get all the benefits. It’s made a huge difference to how I feel in the morning”. Emma, verified patient, Oxford. Unlike some iron tablets that can cause side effects such as nausea, constipation, or a metallic taste, IBSA Iron ODF uses ferric pyrophosphate, a gentler form of iron, alongside a minimalist ODF formulation. This form bypasses much of the digestive system, helping reduce irritation whilst maintaining comparable absorption to some Iron tablets². It’s also gluten-free, lactose-free, and vegan friendly and contains less than 1 kcal per film.Who is it for?IBSA Iron ODF is particularly suited to: Women during menstruation, pregnancy, or postpartum recoveryAthletes with higher iron needsPeople with gastrointestinal absorption issues (e.g. Crohn’s, coeliac disease)Anyone who dislikes or struggles to swallow tablets IBSA Iron ODF is part of a new range of oral film supplements now available from IBSA Care. The range also includes IBSA Vitamin D3 ODF, a 2000 IU supplement formulated to support bone and immune health in individuals with limited sun exposure, and IBSA Vitamin B12 ODF, designed for vegetarians, older adults, and anyone with reduced B12 absorption. All products are based on IBSA’s patented FilmTec® technology, combined with the company’s pharmaceutical expertise and dedication to innovation, providing convenient, high-quality supplements designed for real life. IBSA's ODF technology has been clinically evaluated for iron and vitamin D3 delivery. Studies demonstrate comparable absorption to market-leading capsule formats2 3, offering reassurance that these new supplements are as effective as they are easy to take.Visit www.ibsacare.co.uk for further information. Helen Pope, HPPR+44 (0)7879 818247, helen@helenpopepr.co.uk References1. Cook et al., 2024 – Dysphagia prevalence and patient preferences across Brazil, UK, China, and Indonesia. Healthcare (Basel), 12(18):1827. 2. Cupone et al., 2023 – Clinical evaluation of iron orodispersible film (ODF). Pharmaceutics, 15(6):1575. 3. Cupone et al., 2020 – Development and stability of vitamin D3 ODF formulation. Molecules, 25:5851. UKODF00003DOP: July 2025 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c5e03731-fb0b-409a-afd9-fc5e09a52f63

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	China	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Hypoparathyroidism	Canada	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 3	South Korea	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	Italy	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	Denmark	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	Denmark	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	Denmark	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Rheumatoid Arthritis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Diabetes Mellitus, Type 2	Phase 2	Denmark	University of Aarhus	01 Dec 2008
Complicated urinary tract infection	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02563015 (Pubmed \| Am J Clin Nutr)	Phase 3	Vitamin D Deficiency	98	cholecalciferolvitamin D3 (1000 IU/d of vitamin D3 supplementation)	eyuwezplbk(yauudkrfys) = not significantly different between groups wdyopqdjru (dbmheopzek ) View more	Positive	01 Nov 2025
				cholecalciferolvitamin D3 (400 IU/d of vitamin D3 supplementation)
NCT04170348 (ViDAS-2, CTgov)	Phase 2	Vitamin a Deficiency \| Asthma \| Vitamin D Deficiency ... View more	58	Daily oral vitamin D3, 3,333 IU (Daily Oral Vitamin D3)	krtxtbjfzi(wavrggmkgd) = nhxjbsaxfd sdbsburvmh (fezsqesqic, 2.1) View more	-	24 Sep 2025
				Placebo oral tablet+vitamin D3 (Monthly Bolus Oral Vitamin D3)	krtxtbjfzi(wavrggmkgd) = nfbdtjcdgr sdbsburvmh (fezsqesqic, 2.6) View more
NCT03406897 (POSEIDON, CTgov)	Phase 1/2	Diabetes Mellitus, Type 1 \| Hypoglycemia	27	Omega 3 fatty acid+cholecalciferol (Omega-3 and Vitamin D Combination)	jsjbqiexkz(amiggfzziy) = vlphufnwov cvdovuvhzf (basnbxvpmo, xzpwstaoag - vgkizjvicj) View more	-	17 Sep 2025
				cholecalciferol (Vitamin D Only)	jsjbqiexkz(amiggfzziy) = dspoorshnn cvdovuvhzf (basnbxvpmo, kuxljjnqhe - jbvetpvuxw) View more
NCT06539260 (Pubmed \| Sci Rep)	Early Phase 1	Rickets vitamin D deficiency	-	Vitamin D3 supplementation	fvbyvqrjcn(fkdfushuyi) = hgcchazxcx tyadiqrncg (bcgvnkxjfj ) View more	Positive	11 Jul 2025
NCT04621500 (VitD/RNA-seq, CTgov)	Phase 2	Vitamin D Deficiency \| Prostatic Cancer	60	Allostatic Load+cholecalciferol	gwunqcurgj = jmrsujmlcg mfqmnckwzk (swiaidbiua, jrdihjcnfv - okxamjofrb) View more	-	04 Jul 2025
NCT04278573 (Pubmed \| J Prim Care Community Health)	Phase 2	Warts	77	Intralesional Vitamin D3 12 000 IU	qiariyogfk(hiefdmunwl): OR = 0.31 (95.0% CI, 0.01 - 10.3), P-Value = 0.51 View more	Negative	01 Jul 2025
				Placebo
NCT01463813 (Finnish Vitamin D Trial, Pubmed \| J Gerontol A Biol Sci Med Sci)	Not Applicable	Well Aging serum 25-hydroxyvitamin D concentration	2,492	Vitamin D3 (Placebo)	wswfnjywrg(zinpkothsp) = without statistically significant differences in the event rates between the three arms unynyaldad (ycjyaukddz ) View more	Negative	10 Jun 2025
				Vitamin D3 1600 IU/day
NCT04262479 (GADinLADA, CTgov)	Phase 2	Latent Autoimmune Diabetes in Adults	14	recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel+Vitamin D	blgsxtogxp = plvahkultp gydynjhcjg (lubxhywgng, hthiroovin - fihgkfelss) View more	-	08 Jun 2025
NCT04428359 (Pubmed \| Health Sci Rep)	Not Applicable	Warts	61	Intralesional MMR Vaccine	czbggjeyrs(jnqnnmjjjk) = rare with MMR axwwgrtgms (hirrnnlqbx ) View more	Positive	01 May 2025
				Intralesional Vitamin D3
NCT01817166 (D-Lay MS, NEWS \| Pubmed) Manual	Phase 3	Multiple Sclerosis	316	cholecalciferol	lgdzloisld(oejwodiggh) = xfrbjfkivm sfbjtszazm (hvanfjgbbq ) View more	Positive	11 Mar 2025
				Placebo	lgdzloisld(oejwodiggh) = oihzjqlqmf sfbjtszazm (hvanfjgbbq ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colecalciferol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation